View Author
patient hepatitis treatment study therapy hepatitis b response level liver hbeag group model peg-ifn baseline genotype hbsag effect decline hbv dna analysis virus disease hepatology follow-up serum signi result hbeag loss month peginterferon table infection interferon hepatitis c factor lamivudine signi ficantly university cirrhosis prediction hepatitis b virus hbv dna decline gastroenterology combination survival figure hbeag-positive score count number hepatitis b patients outcome hospital rotterdam value ribavirin hbv dna levels responder portal hbv genotype range netherland cancer placebo hansen hbeag-negative hbeag seroconversion population transplantation marker fi brosis probability mutation trial brosi hbv-dna difference department schalm sw incph
10 Most Recent Publications
|
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis
(Article)
Zoutendijk, R. Reijnders, J.G.P. Berg, T. Hansen, B.E. Sonneveld, M.J. Wedemeyer, H. Janssen, H.L.A. Zoulim, F. Brown, A. Mutimer, D.J. Deterding, K. Hofmann, W.P. Petersen, J. Fasano, M. Buti, M. |
2013-05-01
|
|
Precore and core promoter mutants are associated with higher HBeAg seroconversion but low disease remission rates in HBV patients treated with nucleos(t)ide analogues
(Article)
Zoutendijk, R. Sonneveld, M.J. Reijnders, J.G.P. Vuuren, A.J. van Biesta, P.J. Hansen, B.E. Boonstra, A. Janssen, H.L.A. |
2013-05-01
|
|
Genetic polymorphisms in innate immunity receptors do not predict the risk of bacterial and fungal infections and acute rejection after liver transplantation
(Article)
Mare-Bredemeijer, E. de Mancham, S. Kazemier, G. Janssen, H.L.A. Metselaar, H.J. Kwekkeboom, J. Utomo, W.K. Canck, I. de Thielen, M. van Meester, E. de Rossau, R. Laan, L.J.W. van der Hansen, B.E. Tilanus, H.W. |
2013-04-01
|
|
Anticoagulant therapy in patients with non-cirrhotic portal vein thrombosis: Effect on new thrombotic events and gastrointestinal bleeding
(Article)
Spaander, V.M.C.W. Hoekstra, J.W. Hansen, B.E. Buuren, H.R. van Leebeek, F.W.G. Janssen, H.L.A. |
2013-03-01
|
|
Long-term response rates of successful hepatitis B vaccination in HIV-infected patients
(Article)
Lopes, V.B. Hassing, R.J. Vriessluijs, T.E.M.S. de El Barzouhi, A. Hansen, B.E. Schutten, M. Man, R.A. de Ende, M.E. van der |
2013-02-04
|
|
Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension
(Article)
Schouten, J.N. Ende, M.E. van der Koëter, T. Rossing, H.H.M. Komuta, M. Verheij, J. Valk, M. van der Hansen, B.E. Janssen, H.L.A. |
2012-09-17
|
|
Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension
(Article)
Schouten, J.N. Ende, M.E. van der Koëter, T. Rossing, H.H.M. Komuta, M. Verheij, J.B. Valk, M. van der Hansen, B.E. Janssen, H.L.A. |
2012-09-17
|
|
Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon α-2a: Progressive decrease in hepatitis B surface antigen in responders
(Article)
Rijckborst, V. Ferenci, P. Vuuren, A.J. van Boucher, C.A.B. Hansen, B.E. Janssen, H.L.A. Akdogan, M. Pinarbasi, B. Borg, M.J. ter Simon, K. Flisiak, R. Akarca, U.S. Raptopoulou-Gigi, M. Verhey, E. |
2012-09-01
|
|
Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B
(Article)
Sonneveld, M.J. Rijckborst, V. Zeuzem, S. Heathcote, E.J. Simon, K. Senturk, H. Pas, S.D. Hansen, B.E. Janssen, H.L.A. |
2012-07-01
|
|
Continuous interferon-α,2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients
(Article)
Roomer, R. Bergmann, J.F. Boonstra, A. Hansen, B.E. Haagmans, B.L. Kwadijk-De Gijsel, S. Vuuren, A.J. van Knegt, R.J. de Janssen, H.L.A. |
2012-06-05
|
